Six publications this week:

• Content validity, face validity and comprehensiveness of generic quality-of-life measures in adults and children with rare genetic conditions and their carers: a think aloud qualitative study | link
• Diagnostic Performance and Cost-Effectiveness of BALF mNGS in Older Adults with Pulmonary Infections | link
• Effects of a clinical metagenomics intervention on clinical outcomes, healthcare costs, and health-related quality of life in patients with sepsis or septic shock: results of the randomized-controlled DigiSep trial | link
• The costs of genomic newborn screening in England: A micro-costing analysis from the Generation Study | link
• Determinants of willingness-to-pay for genomic sequencing in hong kong: psycho-socio-economic factors and healthcare engagement from a contingent valuation study | link
• Exploratory Economic Evaluation of a Genome Precision Report in Kidney and Liver Transplantation Care | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

Two publications this week:

• The IMPACT-FH Renewal Protocol: Evaluating FH Cascade Testing Implementation in Primary Care through a Pragmatic Trial, Economic Evaluation, and Mixed-Methods Sustainability Assessment | link
• Modelling the cost-effectiveness of non-invasive prenatal testing in the English sickle cell and thalassaemia screening pathway | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

Three publications this week:

• Cost-effectiveness of genome-guided statin treatment for hypercholesterolemia | link
• Health economic evaluations of genomic newborn screening: Approaches by studies within the international consortium on newborn sequencing | link
• Implementing whole genome and transcriptome sequencing for cancer patients in routine healthcare: a comprehensive guide to costing | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

Four publications this week:

• Cost-effectiveness of DPYD genotyping prior to fluoropyrimidine-based treatment for colorectal cancer in Wales | link
• The cost and cost-effectiveness of whole-exome and whole-genome sequencing: a systematic literature review | link
• Comparative Costs and Diagnostic Yields of Next-Generation Sequencing Versus Muscle Biopsy for Multiplex Ligation-Dependent Probe Amplification-Negative Duchenne Muscular Dystrophy | link
• A Value-Based Evaluation Framework for Guiding the Adoption and Scale-Up of Cancer Genomics Interventions | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

One publication this week:

• A global economic perspective on whole-genome sequencing strategies for pathogens: continuous surveillance versus outbreak-triggered investigations | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

Four publications this week:

• The potential survival gain and cost-effectiveness of circulating tumor DNA-guided treatment switching in advanced non-small cell lung cancer: A simulation modeling study | link
• Life Years Gained and Healthcare Dollars Saved: National Economic Evidence Supporting Comprehensive Genomic Profiling as Standard of Care for Canadian Cancer Patients | link
• Only Economic Solutions Will Enable the Implementation of Genetic Sequencing in the Real World | link
• The Concept of Personal Utility in Genomic Testing: Three Ethical Tensions | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

Nine publications this week:

• Cost-effectiveness of exagamglogene autotemcel gene-edited therapy in patients with transfusion-dependent β-thalassemia in the United States | link
• Cost-effectiveness analysis of four sampling and genomic testing strategies for patients with advanced non-small-cell lung cancer in Australia | link
• Estimating the potential economic and health impact of integrated genomic surveillance in a hospital setting | link
• Direct cost savings associated with reduction in plasma metagenomic sequencing | link
• Assessing Willingness to Pay for Genetic Testing Among Adults: A Cross-Sectional Study Using Data from the Omnibus Survey 2022 | link
• Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer | link
• Costs and benefits of whole-exome, whole-transcriptome sequencing versus 50-gene panels for genomic profiling in solid tumors | link
• The Impact of Adopting Whole-Genome Sequencing for Tuberculosis Diagnosis in China: A Cost-Effectiveness Analysis | link
• Diagnostics investments and disease burden | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

Four publications this week:

• Systematic Review of Genomic-Based Risk Stratification in Localised Prostate Cancer Treatment Optimisation: Clinical Impact and Health Economic Evidence | link
• Genomic Testing in Australia: A Budget Impact Analysis Using Diffusion Modeling From a Healthcare System Perspective | link
• A multistage cost-effective strategy for the molecular diagnosis of unexplained vision loss patients: practice in inherited ocular fundus disease | link
• Fast Science, Slow Evaluation: What Makes Health Technology Assessment of Genetic and Genomic Technologies So Complicated? A Systematic Review of Methodological Challenges and Identified Suggestions | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

Two publications this week:

• A value-based evaluation framework for guiding the adoption and scale-up of cancer genomics interventions | link
• Accounting for Genomic Testing Costs in Cost-Effectiveness Evaluations: Challenges and Lessons Learned from the NICE Single Technology Appraisal of Erdafitinib for Treating Unresectable or Metastatic Urothelial Cancer with FGFR3 Alterations After a PD-1 or PD-L1 Inhibitor | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

Four publications since the last update:

• Evaluating the Cost of Genomic Testing for Biomarker-Driven Therapies in Oncology | link
• Clinical and economic benefits of combined genetic and genomic testing strategies to guide treatment decisions for patients with HR+/HER2- breast cancer in the US | link
• Is liquid biopsy a cost-effective method to diagnose Burkitt Lymphoma in children and young adults? A health economic evaluation in Tanzania | link
• Cost-effectiveness of exagamglogene autotemcel gene-edited therapy in patients with sickle cell disease with recurrent vaso-occlusive crises in the United States | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.